Oncostatin M reverses ABCG2-mediated mitoxantrone resistance

Mitoxantrone resistant variant of SW620 line was developed, characterized and subsequently used as a model system to determine oncostatin M ability to modulate MDR phenomenon. The selection regimen allowed for overexpression of ABCG2 and ABCB1 both at the RNA and protein level, which was further confirmed by functional assays. Oncostatin M supplementation resulted in partial reversal of MDR phenotype by decreasing overexpression of ABCG2 demonstrating for the first time the ability of this cytokine for selective down-regulation of one of MDR proteins. •New MDR clone of SW620 was obtained by mitoxantrone selection.•SW620Mito variant significantly overexpressed ABCG2 transporter.•Oncostatin M was used as a novel approach to overcome MDR phenotype. This cytokine decreased overexpression of ABCG2.•Oncostatin M mitigate resistance toward series of ABCG2 substrates (like mitxantrone, elacridar, lisitnib, etc.).•Fluorescent dyes transport assays were performed revealing decreased transport capabilities mediated by ABCG2.